Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. IVVD
IVVD logo

IVVD

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

IVVD News

Invivyd Grants Stock Options to New Employees

17h agoNewsfilter

Invivyd's Q1 Revenue Misses Expectations, Shares Plummet

May 14 2026stocktwits

Invivyd Q1 2026 Earnings Call Highlights

May 14 2026seekingalpha

Invivyd Reports Q1 2026 Financial Results with Revenue Growth

May 14 2026seekingalpha

Invivyd to Announce Q1 Earnings on May 14

May 13 2026seekingalpha

Invivyd's Antibody Study Shows Low Side Effects

May 11 2026Newsfilter

Invivyd Chairman to Speak at Health Summit

Apr 20 2026Newsfilter

Invivyd Reports Progress in Late-Stage Trial for COVID-19 Therapy VYD2311

Apr 09 2026seekingalpha

Invivyd Announces Progress in COVID-19 Study and New Measles Antibody Candidate

Apr 09 2026Newsfilter

Invivyd Launches National Antibody Education Campaign

Apr 07 2026Newsfilter

Invivyd Grants Stock Options to New Employees

Apr 06 2026Newsfilter

BETA Technologies Reports Disappointing Q4 Results

Mar 09 2026Benzinga

Invivyd Q4 2025 Earnings Call Highlights

Mar 05 2026seekingalpha

Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates

Mar 05 2026Newsfilter

Invivyd Set to Announce FY Earnings with Significant Growth Expectations

Mar 04 2026seekingalpha

Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311

Feb 03 2026seekingalpha